CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 47 enrolled
Drug / intervention
niacin +1 moredietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03462680
NCT03462680N/ACompleted
CompareCT.gov

GPR109A and Parkinson's Disease: Role of Niacin in Outcome Measures

VA Office of Research and Development·interventional·Posted Mar 12, 2018·Updated Nov 17, 2021

In Brief

A clinical study evaluating niacin and placebo for Parkinson's Disease. Completed, enrolled 47 participants across 1 site.

Detailed Summary

Inflammation plays a central role in Parkinson's disease. The use of anti-inflammatory drugs was found to reduce the risk of PD . Niacin may play an important role in reducing inflammation in PD. The investigators also found that individuals with PD have a chronic niacin deficiency . The purposes of this study are to (1) examine the blood, urine and spinal fluid of persons with Parkinson's to look for evidence of inflammation and; (2) whether 6 months of vitamin B3 supplements may reduce the inflammation and/or improve symptoms.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsParkinson's Disease
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
2017201820192020202120222023202420252026
First PostedMar 12, 2018
Enrollment StartSep 28, 2016
Primary CompletionApr 23, 2020
TodayJul 2, 2026
Enrollment to primary: 3.6 yearsPosted 8.3 years ago

Interventions

niacindietary

Niacin or nicotinic acid 250 mg tablets

placeboother

placebo tablet